Jeffrey Schouten

Jeffrey Schouten

Auto-generated profile, based on publicly available information

Jeffrey Schouten

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
KHKirsten Hauge
Kirsten Hauge
AMAmalia Magaret
Amalia Magaret
CMConstance Mao
Constance Mao
JSJeffrey Schouten
Jeffrey Schouten
AWAnna Wald
Anna Wald
Persistent infection with oncogenic human papillomavirus (HPV) has been linked to 70% of vulvar and 90% of anal cancers, causing more than 45 000 cases worldwide each year.1 In the United States, more than 10 000 cases are diagnosed annually, and most are HPV-16 related.2 Incidence rates of anal and vulvar cancer have increased over the past decades in the United States, particularly among high-risk groups.3 Specifically, among US HIV-infected men who have sex with men (MSM), the incidence of anal cancer (78 of 100 000) currently exceeds the incidence of cervical cancer in sub-Saharan Africa (55 of 100 000 women).4,5 Locally invasive anal and vulvar cancers are associated with 48% and 59% 5-year survival, respectively.6

1 September 2012 in Progress in Community Health Partnerships: Research, Education, and Action
Verified
Journal Article
Open access
PDF file
JKJonathan M. Kagan
Jonathan M. Kagan
SRScott R. Rosas
Scott R. Rosas
RSRona L. Siskind
Rona L. Siskind
RCRussell D. Campbell
Russell D. Campbell
DGDaniel Gondwe
Daniel Gondwe
JSJeffrey T. Schouten
Jeffrey T. Schouten
Background: Community engagement has been a cornerstone of National Institute of Allergy and Infectious Diseases (NIAID)'s HIV/AIDS clinical trials programs since 1990. Stakeholders now consider this critical to success, hence the impetus to develop evaluation approaches. Objectives: The purpose was to assess the extent to which community advisory boards (CABs) at HIV/AIDS trials sites are being integrated into research activities. Methods: CABs and research staff (RS) at NIAID research sites were surveyed for how each viewed (a) the frequency of activities indicative of community involvement, (b) the means for identifying, prioritizing, and supporting CAB needs, and (c) mission and operational challenges. Results: Overall, CABs and RS share similar views about the frequency of community involvement activities. Cluster analysis reveals three groups of sites based on activity frequency ratings, including a group notable for CAB-RS discordance. Conclusions: Assessing differences between community and researcher perceptions about the frequency of and challenges posed by specific engagement activities may prove useful in developing evaluation tools for assessing community engagement in collaborative research settings.

2 September 2025
Verified
Other
Open access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Supplementary Table S1 shows HPV subtypes detected with HRA HSIL disease extent

11 July 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Background: Molecular biomarkers could enhance anal cancer screening accuracy in people living with human immunodeficiency virus. We assessed the performance of human papillomavirus (HPV) 16/18 E6 oncoprotein in detecting anal high-grade squamous intraepithelial lesions (HSIL) in men living with human immunodeficiency virus. Methods: We analyzed clinical data from 125 clinic visits of 82 men living with human immunodeficiency virus who underwent high-resolution anoscopy in Seattle, Washington (2015–2016), including the presence and extent of HSIL. Anal brush specimens were tested for high-risk HPV DNA, with HPV-16/18–positive samples further tested for E6 oncoprotein. Sensitivity, specificity, positive predictive value, and negative predictive value of HPV-16/18 E6 oncoprotein for HSIL were calculated, along with prevalence ratios with 95% confidence intervals. Results: Forty-eight (38.4%) samples were HPV-16/18 positive, including three E6 positive. Forty-nine (39.2%) samples had corresponding HSIL. Specificity and positive predictive value of HPV-16/18 E6 for HSIL was 100%, and the prevalence ratio was 7.33 (95% confidence interval, 2.44–22.07) for HPV-16/18 E6–positive versus high-risk HPV–negative samples. Sensitivity for HSIL, however, was only 6.1%, with a moderate negative predictive value (62.3%). Two of four persons with HSILs with >75% disease extent had corresponding HPV-16/18 E6–positive samples, whereas none of 30 persons with <25% extent did. Conclusions: The HPV-16/18 E6 oncoprotein has potential utility as a triage biomarker for identifying and prioritizing lesions at the highest risk for progression. Impact: People living with human immunodeficiency virus are at an increased risk of anal cancer and would benefit from improved screening methods. Further research may elucidate the role of HPV-16/18 E6 oncoprotein in anal cancer prevention, alone or combined with other biomarkers.

2 September 2025
Verified
Other
Open access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Supplementary Figure S1 is a flowchart Flowchart showing participant enrollment, sample inclusion, and clinical outcomes.

2 September 2025
Verified
Other
Open access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Background:Molecular biomarkers could enhance anal cancer screening accuracy in people living with human immunodeficiency virus. We assessed the performance of human papillomavirus (HPV) 16/18 E6 oncoprotein in detecting anal high-grade squamous intraepithelial lesions (HSIL) in men living with human immunodeficiency virus.Methods:We analyzed clinical data from 125 clinic visits of 82 men living with human immunodeficiency virus who underwent high-resolution anoscopy in Seattle, Washington (2015–2016), including the presence and extent of HSIL. Anal brush specimens were tested for high-risk HPV DNA, with HPV-16/18–positive samples further tested for E6 oncoprotein. Sensitivity, specificity, positive predictive value, and negative predictive value of HPV-16/18 E6 oncoprotein for HSIL were calculated, along with prevalence ratios with 95% confidence intervals.Results:Forty-eight (38.4%) samples were HPV-16/18 positive, including three E6 positive. Forty-nine (39.2%) samples had corresponding HSIL. Specificity and positive predictive value of HPV-16/18 E6 for HSIL was 100%, and the prevalence ratio was 7.33 (95% confidence interval, 2.44–22.07) for HPV-16/18 E6–positive versus high-risk HPV–negative samples. Sensitivity for HSIL, however, was only 6.1%, with a moderate negative predictive value (62.3%). Two of four persons with HSILs with >75% disease extent had corresponding HPV-16/18 E6–positive samples, whereas none of 30 persons with <25% extent did.Conclusions:The HPV-16/18 E6 oncoprotein has potential utility as a triage biomarker for identifying and prioritizing lesions at the highest risk for progression.Impact:People living with human immunodeficiency virus are at an increased risk of anal cancer and would benefit from improved screening methods. Further research may elucidate the role of HPV-16/18 E6 oncoprotein in anal cancer prevention, alone or combined with other biomarkers.